Developmental Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia.
Dev Med Child Neurol. 2010 Jan;52(1):79-86. doi: 10.1111/j.1469-8749.2009.03387.x. Epub 2009 Jul 3.
To test the effectiveness of repeat botulinum toxin A (BoNT-A) injections in the affected arm of 22 children with hemiplegic cerebral palsy (19 males, three females), aged 1 year 10 months to 4 years 10 months (mean 3y 8mo, SD 9mo) in a randomized controlled trial.
Children received either three series of BoNT-A injections plus twice-weekly occupational therapy (OT) or OT alone in 16-week cycles. Muscles targeted at each injection cycle in the 11 children receiving BoNT-A+OT were the adductor pollicis (n=9), flexor pollicis longus (n=5), flexor digitorum superficialis (n=8), flexor digitorum profundus (n=8), flexor carpi radialis (n=2), flexor carpi ulnaris (n=6), pronator teres (n=10), and biceps brachii (n=11). Parental perception of treatment efficacy was assessed using the Canadian Occupational Performance Measure (COPM) and the Goal Attainment Scale (GAS), quality of movement using the Quality of Upper Extremity Skills Test (QUEST), fine motor skills using the Peabody Developmental Motor Scale - Fine Motor (PDMS-FM), and spasticity using the Modified Tardieu Scale (MTS). Between-group differences at 12 months were analysed using independent-sample t-tests.
All children were at Gross Motor Function Classification System levels I (BoNT-A+OT n=6; OT n=8) or II (n=5 and n=3 respectively) and were too young to be classified using the Manual Ability Classification System. The BoNT-A+OT group had higher COPM performance scores (mean difference -0.8, 95% confidence interval [CI] -1.5-0.0) and higher GAS T scores (mean difference -6.9, 95% CI -13.8 to -0.1]). No significant difference was found for the COPM satisfaction, PDMS-FM, or QUEST scores. The BoNT-A+OT group showed progressive reduction in spasticity compared with the OT group. At study completion MTS mean difference was 50.0 degrees (95% CI 22.4-77.6) for pronators and 20.9 degrees (95% CI 2.4-39.4) for wrist flexors.
Repeat BoNT-A injections in the upper limb combined with OT resulted in progressively reduced spasticity and improved parental perception of performance.
在一项随机对照试验中,测试 22 名偏瘫脑瘫儿童(19 名男性,3 名女性)的患侧上肢重复注射肉毒毒素 A(BoNT-A)的有效性,这些儿童年龄为 1 岁 10 个月至 4 岁 10 个月(平均 3y 8mo,SD 9mo)。
儿童接受了三系列 BoNT-A 注射加每周两次的职业治疗(OT),或在 16 周的周期内单独接受 OT。在接受 BoNT-A+OT 的 11 名儿童中,每次注射周期的目标肌肉为:内收拇指肌(n=9)、拇长屈肌(n=5)、指浅屈肌(n=8)、指深屈肌(n=8)、桡侧腕屈肌(n=2)、尺侧腕屈肌(n=6)、旋前圆肌(n=10)和肱二头肌(n=11)。采用加拿大职业表现测量(COPM)和目标达成量表(GAS)评估父母对治疗效果的认知,采用上肢技能质量测试(QUEST)评估运动质量,采用 Peabody 发育运动量表-精细运动(PDMS-FM)评估精细运动技能,采用改良 Tardieu 量表(MTS)评估痉挛程度。采用独立样本 t 检验分析 12 个月时的组间差异。
所有儿童的粗大运动功能分类系统水平均为 I 级(BoNT-A+OT 组 n=6;OT 组 n=8)或 II 级(n=5 和 n=3),年龄太小,无法使用手动能力分类系统进行分类。BoNT-A+OT 组的 COPM 表现评分更高(平均差异-0.8,95%置信区间[CI] -1.5-0.0),GAS T 评分更高(平均差异-6.9,95% CI -13.8 至 -0.1)。COPM 满意度、PDMS-FM 或 QUEST 评分无显著差异。与 OT 组相比,BoNT-A+OT 组的痉挛程度逐渐减轻。研究结束时,MTS 平均差异为旋前肌 50.0 度(95% CI 22.4-77.6)和腕屈肌 20.9 度(95% CI 2.4-39.4)。
上肢重复注射 BoNT-A 联合 OT 可导致痉挛程度逐渐减轻,并改善父母对运动表现的认知。